Central in Vivo Nicotinic Acetylcholine Receptor Imaging Agents for Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT)

DOI Web Site Web Site 被引用文献3件 参考文献70件
  • Ogawa Mikako
    Photon Medical Research Center, Hamamatsu University School of Medicine
  • Tsukada Hideo
    Central Research Laboratory, Hamamatsu Photonics K.K.
  • Hatano Kentaro
    National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology
  • Ouchi Yasuomi
    Molecular Imaging Frontier Research Center, Hamamatsu University School of Medicine
  • Saji Hideo
    Graduate School of Pharmaceutical Sciences, Kyoto University
  • Magata Yasuhiro
    Photon Medical Research Center, Hamamatsu University School of Medicine Molecular Imaging Frontier Research Center, Hamamatsu University School of Medicine

この論文をさがす

抄録

Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are useful for non-invasive investigation of brain receptors. With these imaging techniques, changes in brain receptor densities and distributions during chronic drug treatments and disease progressions can be tracked for a long period. Appropriate radiolabeled imaging agents are necessary for PET and SPECT molecular imaging. Nicotinic acetylcholine receptors (nAChRs) play important roles in brain functions. The α4β2 and α7 are the major nAChR subtypes in the brain. To date, several subtype selective radiolabeled ligands for nAChR have been reported. For the α4β2 subtype, some agents are already applied for human studies, but only a few agents are developed for the α7 subtype. Here, we overview our results of [125/123I]5-iodo-3-(2(S)-azetidinylmethoxy)pyridine and 5-[11C]methyl-3-(2-(S)-azetidinylmethoxy)pyridine ([11C]5MA) for α4β2 subtype imaging, and [11C](R)-2-methylamino-benzoic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester ([11C](R)-MeQAA) for α7 subtype imaging.

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (70)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ